Atopic dermatitis (eczema) is a multifactorial chronic inflammatory disease that affects approximately 20% of children and up to 3% of adults globally, increasingly affecting low-income countries as well as developed countries. It is generally treated by the topical application of steroidal drugs that have undersirable side-effects. The development of alternatve therapies for the treatment of atopic dermatitis is therefore an important objective.

​

There is an unmet need for non-corticosteroidal treatment options for both pediatric and adult mild-to-moderate atopic dermatitis populations. 

 

Atopic dermatitis is one of the most common forms of cutaneous allergy. It is particularly prevalent in developed countries (e.g., Australia, USA, Canada, and most European countries), but is becoming increasingly prevelant in low-income countries.